|
Dr. Gillis is a founder and director of Corixa Corp. (aquired by GSK in 2005) and served as the company's CEO since inception and as its Chairman since January of 1999. He is also Founder and director of Immunex Corp. Dr. Gillis served as Director of Research and Development, CSO, and CEO of Immunex's Research and Development subsidiary. Immunex was acquired by Amgen Inc. in 2002. He was previously Professor at the University of Washington. Dr. Gillis is an Immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20). Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978. | 